PRV-211 is under clinical development by Privo Technologies and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData, Phase II drugs for Oral Cavity (Mouth) Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PRV-211 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRV-211 overview
PRV-211 is under development for the treatment of tongue cancer and solid tumors like head and neck, colorectal, cervical/vaginal, anal, lip and oral squamous cell carcinoma and ocular squamous cell carcinoma. The drug candidate is an intra operative chemotherapy developed based on PRV platform technology as a topical patch.
Privo Technologies overview
Privo Technologies (Privo) is a biopharmaceutical company that discovers and develops therapies for cancers. The company is investing PRV111, a therapeutic patch to treat anal, colorectal, genitourinary, nasal, skin, head, neck, and HPV (human papillomavirus vaccines) related cancers; and PRV211, a sterilized rapid release intraoperative chemotherapy patch for the treatment of solid tumors. It evaluates PRV311 program against orthopedic indications; and PRV 411 drug targeting gastrointestinal diseases. The company utilizes PRV (programmed release vehicle) platform technology to enable targeted drug delivery and design alternatives for currently available treatments. Privo is headquartered in Peabody, Massachusetts, the US.
For a complete picture of PRV-211’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
